Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Apr;19(2):45-55.
doi: 10.1007/s11899-023-00721-8. Epub 2024 Jan 9.

Treatment of Richter's Transformation with Novel Therapies

Amneet Bajwa  1 , Alma Habib  1 , Adam S Kittai  2
Affiliations
Review

Treatment of Richter's Transformation with Novel Therapies

Amneet Bajwa et al. Curr Hematol Malig Rep. 2024 Apr.

Abstract

Purpose of review: This review presents recently published clinical trial data and ongoing investigations regarding the treatment of Richter's transformation (RT).

Recent findings: Recently, numerous approaches have been investigated for the treatment of RT including: traditional chemoimmunotherapy regimens combined with targeted agents such as BTKi and BCL2i; immunotherapy combined with targeted agents; non-covalent BTKis; bispecific T cell engagers; and CART therapy. In addition, various novel targeted agents are currently being studied for the treatment of RT in phase 1 and 2 clinical trials. Standard of care treatment with chemoimmunotherapy for RT has limited efficacy in achieving durable remissions. Here, we review recent data on the use of combination treatments and targeted agents in RT. Although some progress has been made in the investigation to optimize treatment of RT, further study is needed to evaluate long term outcomes of recently published trials and test efficacy of upcoming novel agents.

Keywords: Chronic lymphocytic leukemia; Novel therapies; Richter’s syndrome; Richter’s transformation; Therapy.

PubMed Disclaimer

Conflict of interest statement

A.B., and A.H. have no disclosures. A.S.K. receives research funding from AstraZeneca and BeiGene, and has consulted for Abbvie, AstraZeneca, Beigene, BMS, Kite a Gilead company, Janssen, and Lilly@Loxo, and is on the speaker’s bureau for BeiGene.

References

    1. Tsimberidou AM, O'Brien S, Khouri I, Giles FJ, Kantarjian HM, Champlin R, et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol. 2006;24(15):2343–2351. - PubMed
    1. Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, et al. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 2020;105(3):765–773. - PMC - PubMed
    1. Pistoia V, Roncella S, Di Celle PF, Sessarego M, Cutrona G, Cerruti G, et al. Emergence of a B-cell lymphoblastic lymphoma in a patient with B-cell chronic lymphocytic leukemia: evidence for the single-cell origin of the two tumors. Blood. 1991;78(3):797–804. - PubMed
    1. Klener P, Fronkova E, Berkova A, Jaksa R, Lhotska H, Forsterova K, et al. Mantle cell lymphoma-variant Richter syndrome: detailed molecular-cytogenetic and backtracking analysis reveals slow evolution of a pre-MCL clone in parallel with CLL over several years. Int J Cancer. 2016;139(10):2252–2260. - PubMed
    1. Parikh SA, Rabe KG, Call TG, Zent CS, Habermann TM, Ding W, et al. Diffuse large B-cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients. Br J Haematol. 2013;162(6):774–782. - PMC - PubMed

Publication types

MeSH terms